miércoles, 31 de diciembre de 2025
FDA Approves First Oral Treatment for Anemia in Thalassemia, an Inherited Blood Disorder
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216196s003lbl.pdf?utm_medium=email&utm_source=govdelivery
FDA Approves First Oral Treatment for Anemia in Thalassemia, an Inherited Blood Disorder
Last week, the U.S. Food and Drug Administration (FDA) approved Aqvesme (mitapivat) tablets to treat anemia (low levels of red blood cells) in adults with alpha- or beta-thalassemia. This is the first oral treatment option for patients with beta-thalassemia and the first drug approval for patients with alpha-thalassemia.
Disease or Condition
Thalassemia is an inherited blood disorder caused by mutations in the genes responsible for producing alpha- and beta-globins. These globins are components of hemoglobin, a protein in red blood cells that carries oxygen. The abnormal effects on globin chain production damages the red blood cells, reducing their production and increasing their destruction (hemolysis). Some patients with thalassemia may be transfusion-dependent, requiring regular blood transfusions to manage their condition, typically every two to five weeks.
Data Supporting Aqvesme
The efficacy and safety of Aqvesme were evaluated in two multinational, randomized, double-blind, placebo-controlled clinical studies.
The ENERGIZE-T study evaluated 258 adults with transfusion-dependent thalassemia, with 171 adults receiving Aqvesme and 87 receiving placebo. Efficacy was based upon transfusion reduction response, defined as greater than 50% reduction in the number of red blood cell units transfused with a reduction of at least two units in any consecutive 12-week period between the baseline visit and Week 48. A higher proportion of patients taking Aqvesme achieved a transfusion reduction response (30%) compared with the placebo group (13%).
A second trial, the ENERGIZE study, evaluated Aqvesme in 194 adults with non-transfusion-dependent thalassemia over 24 weeks, with 130 adults receiving Aqvesme daily and 64 receiving placebo. Efficacy was based upon hemoglobin response (a measure of the improvement in anemia), defined as a ≥1 g/dL increase from baseline in mean hemoglobin concentration at Week 24. A higher proportion of patients taking Aqvesme achieved a hemoglobin response (42%) compared with the placebo group (2%).
Another efficacy endpoint in the ENERGIZE study assessed the mean change from baseline in fatigue-related symptoms and impacts using a patient-reported outcome instrument, the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue). The FACIT-F total score has a range of 0 to 52, with higher scores indicating less fatigue. At baseline, the mean FACIT-F score was approximately 36. Patients treated with Aqvesme had a mean increase in the FACIT-F total score of 4.9 compared to a mean increase of 1.5 in patients taking placebo.
The recommended dosage for Aqvesme is 100 mg orally twice daily with or without food.
Safety Information
Aqvesme is only available through a restricted program called the Aqvesme Risk Evaluation and Mitigation Strategies (REMS) because of the risk of liver toxicity observed in the clinical trials.
The most common side effects of Aqvesme are headache and insomnia. More safety information is available in the prescribing information.
Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition Authors: Kelly Shanahan, MD; Sara Tolaney, MD, MPH; Virginia Kaklamani, MD, DSc; Sarah R. Donahue, MPH, NP, AOCNP; Abigail Shockley, PharmD, BCOP
https://www.medscape.org/viewarticle/communicating-enhance-care-through-data-and-patient-2025a1000uqi?page=1%3Fsrc%3Dmkmcmr_reeng_recap_mscpedu_activity&uac=148436CN&sso=true
Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition
Below are some key learning points to help reinforce the impact of this activity.
☑ Education on self-monitoring can increase patient empowerment.
☑ The cancer care team should implement shared decision-making for optimal patient outcomes.
☑ Benefits of transitioning from fulvestrant to oral selective estrogen receptor degraders (SERDs) include fewer clinic visits and more patient independence.
☑ Elacestrant and imlunestrant are 2 oral SERDs approved by the FDA for the treatment of ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancers with disease progression following at least 1 line of endocrine therapy.
☑ There are differences in toxicity profiles between the oral SERDs, which need to be managed accordingly.
Report on the Use of PFAS in Cosmetic Products and Associated Risks
https://www.fda.gov/media/190319/download?attachment=&utm_medium=email&utm_source=govdelivery
FDA Finds Insufficient Data to Determine Safety of PFAS in Cosmetic Products
December 30, 2025
Dear International Colleague,
The U.S. Food and Drug Administration has released a congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) evaluating the use of perfluoroalkyl and polyfluoroalkyl substances (PFAS) in cosmetic products. While the report reviews available scientific evidence on potential safety concerns, the FDA’s evaluation did not reach definitive safety determinations and underscores significant uncertainty due to gaps in existing data on PFAS exposure through cosmetics.
“In accordance with our congressional mandate, the FDA released its assessment of PFAS in cosmetic products,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety. This lack of reliable data demands further research. Consistent with the MAHA Strategy Report, the FDA will continue working with the CDC and EPA to update and strengthen recommendations on PFAS across the retail and food supply chain.”
https://www.whitehouse.gov/wp-content/uploads/2025/09/The-MAHA-Strategy-WH.pdf?utm_medium=email&utm_source=govdelivery
Based on mandatory cosmetic product listing data submitted to the FDA, 51 PFAS are used in 1,744 cosmetic formulations. To assess safety, the FDA evaluated the 25 most frequently used PFAS, which represent approximately 96% of PFAS intentionally added to cosmetic products. The agency found that “toxicological data for a majority of these PFAS are incomplete or unavailable,” limiting its ability to fully assess risk. The FDA’s ability to effectively collect toxicology data was limited by the fact that most of the data is not publicly available. While five PFAS appeared to present low safety concerns under their intended conditions of use, the safety of most PFAS could not be definitively established, and one PFAS was identified as having a potential safety concern with significant remaining uncertainty.
The report focuses on PFAS intentionally added to cosmetic products as ingredients, rather than PFAS that may be present as contaminants. PFAS are synthetic chemicals used for properties such as water resistance, durability, and texture modification, but their persistence and potential toxicity have raised health and environmental concerns and prompted increasing regulatory scrutiny at the state, federal, and global levels.
There are currently no federal regulations that specifically prohibit PFAS intentionally added to cosmetic products. However, consistent with FDA enforcement policies, the agency will take appropriate action if safety concerns emerge related to such cosmetic products.
The FDA will continue to monitor emerging scientific data and devote additional resources to address data gaps, supporting the Department of Health and Human Services’ Make America Healthy Again efforts to reduce PFAS across the food and consumer product supply chain through expanded testing, monitoring, and surveillance.
For more information on PFAS in cosmetic products, visit the FDA’s website:
https://www.fda.gov/cosmetics/cosmetic-ingredients/and-polyfluoroalkyl-substances-pfas-cosmetics.
https://www.fda.gov/cosmetics/cosmetic-ingredients/and-polyfluoroalkyl-substances-pfas-cosmetics?utm_medium=email&utm_source=govdelivery
HAMRLNC: a comprehensive and scalable pipeline for integrated epitranscriptomic analysis Chosen E. Obih [1,†] , Jiatong Li [2,3,†] , Giovanni Melandri [1,4] , Duke Pauli [1,4] , Eric Lyons [1] , Andrew D. L. Nelson [5] , Brian D. Gregory* [2]
https://www.academia.edu/3064-9765/2/4/10.20935/AcadMolBioGen8059
As sequencing technologies advance and costs decline, there has been a surge in the application of RNA sequencing (RNA-seq) to understand the effects of gene expression regulation on specific biological processes. In addition to the typical uses of RNA-seq for transcriptomics, gene annotation, novel gene discovery, and network analysis, these data can enable a deeper understanding of cellular processes through the identification of RNA modifications (epitranscriptome) and long non-coding RNAs (lncRNAs). To expedite discovery, we developed a portable, centralized computational pipeline for the high-throughput annotation of modified ribonucleotides and long non-coding ribonucleic acids (HAMRLNC). HAMRLNC differs from existing methods by integrating three workflows for transcript abundance quantification, RNA modification inference, and lncRNA annotation using the same RNA-seq pre-processing and mapping steps. This facilitates reproducibility across multiple analyses and allows researchers to perform post hoc analyses of archived sequencing data. In addition, we include novel analysis features to enable downstream visualization of annotated modified RNAs. HAMRLNC generates over a dozen well-defined and labeled figures as output, including gene ontology heatmaps, modification enrichment landscapes, and modification clustering statistics.
FDA Approves First Drug to Treat Serious Complication of Stem Cell Transplant
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761152Orig1s000lbl.pdf?utm_medium=email&utm_source=govdelivery
FDA Approves First Drug to Treat Serious Complication of Stem Cell Transplant
Treatment approved for hematopoietic stem cell transplant-associated thrombotic microangiopathy
Action
Last week, the U.S. Food and Drug Administration (FDA) approved Yartemlea (narsoplimab-wuug) injection to treat adults and children 2 years and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) as the first approved treatment option for TA-TMA.
Disease or Condition
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a serious and life-threatening complication of hematopoietic stem cell transplant in which tiny blood clots form in the small blood vessels. This can lead to organ damage, including damage to the kidneys, cardiovascular system, and gastrointestinal tract.
Data Supporting Yartemlea
The efficacy of Yartemlea was assessed in a single-arm, open-label study (TA-TMA Study) of 28 patients, with additional data from 19 patients (6 pediatric patients and 13 adult patients) enrolled in an expanded access program. In the TA-TMA Study, patients either received Yartemlea 4 mg/kg or 370 mg intravenously once weekly.
In the TA-TMA Study, the primary efficacy assessment was the TMA response, defined as improvement in both laboratory TMA markers (lactate dehydrogenase and platelet counts) and either organ function improvement or no need for transfusions. The TA-TMA response was achieved in 61% of patients. In the expanded access program, TA-TMA response was achieved in 67% of pediatric patients and 69% of adult patients.
Safety Information
The most common side effects are viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia (low number of neutrophils, a type of white blood cell), fever, fatigue, and low potassium. Patients should also be monitored for signs of serious infections.
Designations
Yartemlea received Priority Review, Breakthrough Therapy Designation, and Orphan Drug Designation for this indication.
martes, 30 de diciembre de 2025
HR-Positive Breast Cancer
The approval of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) has permanently changed the treatment paradigm of this disease. Clinicians are faced with increasingly complex decision-making and must be educated on the optimal use of these agents in clinical practice. This Clinical Advances educational initiative will assist clinicians in making more informed choices for their patients by discussing recent data and real-world experiences on the efficacy and safety of CDK4/6 inhibitors in different settings and different patient subtypes.
https://www.medscape.org/sites/advances/metastatic-breast-cancer
Israeli study of psychedelic use for treating PTSD could expand trauma care Maayan Hoffman/The Media Line|03:04 +++ + +
Israeli study of psychedelic use for treating PTSD could expand trauma care
Israelis are grappling with rising trauma symptoms in the wake of prolonged war, while mental health services remain stretched far beyond capacity; since Oct. 7 about 3 million adults in Israel experienced anxiety, depression or symptoms of PTSD
Maayan Hoffman/The Media Line|03:04
https://www.ynetnews.com/health_science/article/rkvgu6yezl
Your brain can age more slowly, researchers discover, but it's all up to you
Study finds that optimism, quality sleep and strong social ties are linked to healthier, younger-looking brains, up to eight years below chronological age, even among adults with chronic pain, highlighting lifestyle over age as key to brain health
Eitan Gefen
Eitan Gefen|05:51
https://www.ynetnews.com/health_science/article/rj2rwjg411l
Sleeping poorly at night? Your dental health may be part of the reason
Research over the past decade suggests a two-way link between sleep quality and oral health; here's why the connection exists and what steps can help protect both healthy teeth and restful sleep
Dr. Dan Littner|Updated:Yesterday | 20:21
https://www.ynetnews.com/health_science/article/b1kqvugezx
Breakthrough Israeli tech detects Crohn’s flares before they begin
Two Israeli researchers develop technologies that may help detect Crohn’s and IBD flare-ups early, using a smart stress-monitoring patch and a synthetic biology-based urine test, potentially transforming care for millions of patients worldwide
ynet Global|Yesterday | 08:39
https://www.ynetnews.com/health_science/article/s1vlrjx4we
First in Israel: artificial urinary sphincter implanted in 4 women using robotic surgery
Four women aged 44 to 75 received implants of artificial urinary sphincters through robotic surgery at Galilee Medical Center after other treatments failed; the rare procedure targets severe incontinence, a condition far more common in women
Or Hadar|Yesterday | 02:31
https://www.ynetnews.com/health_science/article/sku2dtcxze
Coffee or tea and bone health? Large study points to a surprising link Tzur Gueta|07:25
Coffee or tea and bone health? Large study points to a surprising link
A decade-long observational study of nearly 10,000 postmenopausal women found slightly higher hip bone density among tea drinkers, while moderate coffee intake showed no harm to bones and very high consumption may be linked to lower density
Tzur Gueta
Tzur Gueta|07:25
https://www.ynetnews.com/health_science/article/ryirwgbnwl
Sex after 65: FDA approves libido-boosting pill for women Tzur Gueta|12.17.25 | 14:52
Sex after 65: FDA approves libido-boosting pill for women
US regulators expand approval of Addyi to postmenopausal women; experts say treatment for low sexual desire remains complex, with limited effectiveness and side effects
Tzur Gueta
Tzur Gueta|12.17.25 | 14:52
https://www.ynetnews.com/health_science/article/ryj2hcczbg
Tel Aviv University researchers uncover how breast cancer spreads to the brain Itay Geffen|Yesterday | 18:52
Tel Aviv University researchers uncover how breast cancer spreads to the brain
A new Tel Aviv University study identifies a genetic and metabolic mechanism that enables breast cancer to spread to the brain, pointing to potential new treatments and improved risk-based monitoring for patients
Itay Geffen|Yesterday | 18:52
https://www.ynetnews.com/health_science/article/b1gp1ngnzg
Common Painkiller Tied to Heart Failure Risk in Older Adults +++++ +++++ +++
BEST OF THE YEAR
Common Painkiller Tied to Heart Failure Risk in Older Adults
https://www.medscape.com/viewarticle/common-painkiller-tied-heart-failure-risk-older-adults-2025a1000kzq?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Disproving Dogma: How the Brain Uses Fat as Fuel
https://www.medscape.com/viewarticle/disproving-dogma-how-brain-uses-fat-fuel-2025a1000jh1?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Forget the Tremor: These Symptoms Come First in Parkinson’s
https://www.medscape.com/viewarticle/forget-tremor-these-symptoms-come-first-parkinsons-2025a1000fj1?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Single Brain MRI Reveals Accelerated Aging, Dementia Risk
https://www.medscape.com/viewarticle/single-brain-mri-reveals-accelerated-aging-dementia-risk-2025a1000ido?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Up to 44% of Dementia Cases Preventable
https://www.medscape.com/viewarticle/44-dementia-cases-preventable-2025a1000f70?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
At-Home Alzheimer’s Testing Is Here: Are Physicians Ready?
https://www.medscape.com/viewarticle/home-alzheimers-testing-here-are-physicians-ready-2025a1000ijh?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
‘Harmless’ Pegivirus Found in Brains of Parkinson’s Patients
https://www.medscape.com/viewarticle/harmless-pegivirus-found-brains-parkinsons-patients-2025a1000kql?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Food Insecurity: A New Risk Factor for Cognitive Decline?
https://www.medscape.com/viewarticle/food-insecurity-new-risk-factor-cognitive-decline-2025a1000qk5?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Is Surgeon Age a Factor in Spine Surgery? No…and Yes
https://www.medscape.com/viewarticle/surgeon-age-factor-spine-surgery-no-and-yes-2025a10009vk?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Regular Flossing Tied to Reduced Ischemic Stroke Risk
https://www.medscape.com/viewarticle/regular-flossing-tied-reduced-ischemic-stroke-risk-2025a10002t7?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
DRUG SPOTLIGHT
Onasemnogene Abeparvovec
https://reference.medscape.com/drug/zolgensma-onasemnogene-abeparvovec-iv-1000314?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Valbenazine
https://reference.medscape.com/drug/ingrezza-valbenazine-1000122?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Teriflunomide
https://reference.medscape.com/drug/aubagio-teriflunomide-999771?ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Could irregular daytime napping serve as an early indicator of underlying health decline? (Medscape AI)
Irregular or prolonged daytime napping patterns in middle- to older-aged adults have been linked to markers of declining health and higher mortality, suggesting that such napping behavior may serve as an early warning sign of underlying pathology.
https://www.medscape.com/ai-search?query=Could%20irregular%20daytime%20napping%20serve%20as%20an%20early%20indicator%20of%20underlying%20health%20decline%3f&ecd=mkm_ret_251229_mscpmrk_neuro_best-of-the-year_etid7995668&uac=148436CN&impID=7995668
Position-wise mutation analysis and temporal changes in SARS CoV-2 Envelope (E) protein variants Anwesa Saha [1,†] , Diganta Mukherjee [1,†] , Aparna Mukhopadhyay* [1]
https://www.academia.edu/3064-9765/2/4/10.20935/AcadMolBioGen8011
SARS CoV-2 is a positive-sense, single-stranded RNA virus. The genome of the virus undergoes numerous mutations, making the development of universally effective drugs challenging. Among its structural proteins, the Envelope (E) protein acts as an ion transporter and virulence factor, making it a potential therapeutic target. Based on the literature available to date, we have identified several functionally important sites in the E protein. These include residues involved in lysosomal deacidification; those of the FYXY motif, involved in amyloid formation in the host; and the PDZ-binding DLLV motif. We focus our analysis on the significance of these residues while also searching for other interesting mutational patterns. In this study, we conducted a comprehensive mutational analysis of the SARS CoV-2 E protein utilizing bioinformatics, statistics, and structural modeling tools. Over 1.4 million sequences were retrieved from the NCBI virus database, filtered, clustered, and aligned chronologically. By employing a combination of web-based tools and in-house Python scripts, we analyzed per-residue Shannon entropy, mutation types, evolutionary pressure, and predicted structural impact (via ∆∆G). We observed a significant number of residues under diversifying selection. This suggests that new amino acids are being sampled at various positions in the protein, providing functional or structural benefits to the virus. A cyclical pattern of mutation and reversion was observed at position 9, stabilizing at a particular mutation. Similar trends appeared at position 11. These mutations may be functionally relevant, which need to be explored in future. However, the key regions have remained conserved over time.
lunes, 29 de diciembre de 2025
Fast Five Quiz: Castration-Resistant Prostate Cancer +++
Fast Five Quiz: Early-Onset Prostate Cancer
Reviewed by Karl J. D'Silva, MD
https://reference.medscape.com/viewarticle/early-onset-prostate-cancer-2025a1000u6q?ecd=wnl_edit_tpal_etid7992704&uac=148436CN&impID=7992704
December 26, 2025
Fast Five Quiz: Castration-Resistant Prostate Cancer
Reviewed by Kyle A. Richards, MD; Karl J. D'Silva, MD
https://reference.medscape.com/viewarticle/fast-five-quiz-castration-resistant-prostate-cancer-2025a1000dxs?ecd=wnl_edit_tpal_etid7992704&uac=148436CN&impID=7992704
December 26, 2025
Fast Five Quiz: Prostate Cancer and Prostate-Specific Membrane Antigen
Reviewed by Karl J. D'Silva, MD
https://reference.medscape.com/viewarticle/prostate-cancer-and-psma-2025a1000u6n?ecd=wnl_edit_tpal_etid7992704&uac=148436CN&impID=7992704
December 26, 2025
Do GLP-1 agonists enhance or suppress sexual desire through reward and hormonal pathways (Medscape AI)
GLP-1 receptor agonists (GLP-1 RAs) appear to exert bidirectional effects on sexual desire by acting on central reward circuitry and, in some populations, by altering sex hormone profiles.
https://www.medscape.com/ai-search?query=Do%20GLP-1%20agonists%20enhance%20or%20suppress%20sexual%20desire%20through%20reward%20and%20hormonal%20pathways&ecd=mkm_ret_251228_mscpmrk_endo_top-content_etid7989629&uac=148436CN&impID=7989629
How can I treat SSRI-related sexual dysfunction (Medscape AI)
https://www.medscape.com/ai-search?query=How%20can%20I%20treat%20SSRI-related%20sexual%20dysfunction&ecd=mkm_ret_251229_mscpmrk_psych_best-of-the-year_etid7990541&uac=148436CN&impID=7990541
A common strategy for managing SSRI-induced sexual dysfunction begins with a careful assessment of benefits versus side effects and may involve medication adjustments, adjunctive therapies, or emerging treatments.
domingo, 28 de diciembre de 2025
EBV and SLE: causal or concurrence? The Lancet Rheumatology ++... ++
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00350-9/fulltext?dgcid=raven_jbs_etoc_email
Jan 2026
Volume 8Number 1e1-e74
https://www.thelancet.com/journals/lanrhe/issue/vol8no1/PIIS2665-9913(25)X0013-8
Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00259-0/abstract?dgcid=raven_jbs_etoc_feature_lanrhe
Fetal and maternal outcome in the pregnancies of patients with systemic sclerosis and very early diagnosis of systemic sclerosis in France: a prospective study
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00185-7/abstract?dgcid=raven_jbs_etoc_feature_lanrhe
How does microgravity-driven bone loss reveal new insights into vitamin D’s role in skeletal health (Medscape AI) +... +++ +++ +++
https://www.medscape.com/ai-search?query=How%20does%20microgravity-driven%20bone%20loss%20reveal%20new%20insights%20into%20vitamin%20D%E2%80%99s%20role%20in%20skeletal%20health&ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Microgravity–induced bone loss models have provided unexpected perspectives on how vitamin D’s active form influences skeletal remodeling, highlighting both its necessity for mineral homeostasis and potential deleterious effects when dysregulated.
Clinical Insights
Cases of ‘Double Diabetes’ Rising: What to Know
https://www.medscape.com/viewarticle/cases-double-diabetes-rising-what-know-2025a1000yg6?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Are Sexual Side Effects Emerging With GLP-1s?
https://www.medscape.com/viewarticle/are-sexual-side-effects-emerging-glp-1-agonists-2025a1000x7g?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Endocrine-Disrupting Chemicals Implicated in HS
https://www.medscape.com/viewarticle/can-endocrine-disrupting-chemicals-plastics-increase-hs-risk-2025a1000y8k?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Interventions
User Engagement in a Weight-Loss App Boosts GLP-1 Success
https://www.medscape.com/viewarticle/user-engagement-weight-loss-app-boosts-glp-1-success-2025a1000xrn?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Low-Fat Vegan Diet Cuts Insulin Use and Costs in T1D
https://www.medscape.com/viewarticle/low-fat-vegan-diet-cuts-insulin-use-and-costs-type-1-2025a1000wcm?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Lifestyle Program Helps T2D Patients at Risk for CKD
https://www.medscape.com/viewarticle/life-medicine-program-helps-patients-t2d-risk-ckd-2025a1000wcb?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
US Drug Spotlight
Semaglutide
https://reference.medscape.com/drug/ozempic-rybelsus-wegovy-semaglutide-1000174?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Tirzepatide
https://reference.medscape.com/drug/mounjaro-zepbound-tirzepatide-4000264?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Exenatide Injectable Solution
https://reference.medscape.com/drug/byetta-exenatide-injectable-solution-342892?ecd=mkm_ret_251214_mscpmrk_endo_lifestyle_etid7952893&uac=148436CN&impID=7952893
Current Status of Gene Therapies in Rare Neuromuscular Disorders Alan Beggs, PhD and Julie A Parsons, MD ++...
The Genetics of Epilepsy: The Importance of Identifying Underlying Causes ++
FEATURED ARTICLES
The Genetics of Epilepsy: The Importance of Identifying Underlying Causes
https://checkrare.com/the-genetics-of-epilepsy-the-importance-of-identifying-underlying-causes/
Isabella Herman, MD, PhD, and Tara Adams, mother of two daughters with epilepsy discuss the challenges of accurate diagnosis and treatment of epilepsy.
Survey Finds Wide-Ranging Impact of X-Linked Hypophosphatemia (XLH) on Patient Experiences
https://checkrare.com/survey-finds-wide-ranging-impact-of-x-linked-hypophosphatemia-on-patient-experiences/
Al Freedman, PhD, Rare Disease Psychologist and Rare Dad, and Jill H. Simmons, MD, Endocrinologist at Vanderbilt University Medical Center in Nashville, Tennessee highlight the burden of XLH on personal finances and out-of-pocket costs, overall health—physical, mental, and social—and access to expert care.
Rare Disease Focus: Congenital and Genetic Conditions ++++++
FDA NEWS
2025 Orphan Drugs: PDUFA Dates and FDA Approvals
https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/
Rare diseases and orphan drugs are at the forefront of novel development and groundbreaking research. Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs.
FDA Approves Selumetinib to Treat Patients With Neurofibromatosis Type 1
https://checkrare.com/fda-approves-selumetinib-to-treat-patients-with-neurofibromatosis-type-1/
The U.S. FDA has approved Koselugo (selumetinib) for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Updates to Prescribing Information for Elevidys in Treatment of Duchenne Muscular Dystrophy
https://checkrare.com/updates-to-prescribing-information-for-elevidys-in-treatment-of-duchenne-muscular-dystrophy/
The U.S. FDA has updated the prescribing information for Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy (DMD).
Approval of Treatment for Patients With Familial Chylomicronemia Syndrome (FCS)
https://checkrare.com/approval-of-treatment-for-patients-with-familial-chylomicronemia-syndrome-fcs/
The U.S. FDA has approved Redemplo (plozasiran) for the treatment of adult patients with familial chylomicronemia syndrome (FCS).
FDA Approves First Treatment for Thymidine Kinase 2 Deficiency
https://checkrare.com/fda-approves-first-treatment-for-thymidine-kinase-2-deficiency/
The U.S. FDA has approved Kygevvi for the treatment of adults and pediatric patients, with an age of symptom onset on or before 12 years, with thymidine kinase 2 deficiency (TK2d).
FDA Approves Elamipretide for Patients With Barth Syndrome
https://checkrare.com/fda-approves-elamipretide-for-patients-with-barth-syndrome/
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Forzinity (elamipretide HCI) for the treatment of patients with Barth syndrome.
CLINICAL PERSPECTIVE +++++
CLINICAL PERSPECTIVE
Positive Topline Results from the CALIBRATE Trial of Encaleret in Patients With Autosomal Dominant Hypocalcemia Type 1
https://checkrare.com/positive-topline-results-from-the-calibrate-trial-of-encaleret-in-patients-with-autosomal-dominant-hypocalcemia-type-1/
Michael A. Levine, MD, ML, Children’s Hospital of Philadelphia, discusses positive topline results from the CALIBRATE trial of encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1).
A Patient’s Diagnostic Journey With Systemic Mastocytosis
https://checkrare.com/a-patients-diagnostic-journey-with-systemic-mastocytosis/
Joan Smith, patient with systemic mastocytosis, discusses her diagnostic journey with systemic mastocytosis (SM).
Results from the ElevAATe Clinical Trial of Efdoralprin Alfa for Patients With AAT Deficiency
https://checkrare.com/results-from-the-elevaate-clinical-trial-of-efdoralprin-alfa-for-patients-with-aat-deficiency/
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses results from the ElevAATe clinical trial of efdoralprin alfa for the treatment of patients with alpha-1 antitrypsin deficiency (AATD).
Results from the TEASE-2 Clinical Trial of Gildeuretinol in Patients With Stargardt Disease
https://checkrare.com/results-from-the-tease-2-clinical-trial-of-gildeuretinol-in-patients-with-stargardt-disease/
Philip J. Ferrone, MD, Vitreoretinal Consultants of New York, discusses results from the TEASE-2 clinical trial of gildeuretinol in patients with Stargardt disease.
New Treatment Option (SAT-3247) for Duchenne Muscular Dystrophy Shows Promise in Early Phase Trial
https://checkrare.com/new-treatment-option-sat-3247-for-duchenne-muscular-dystrophy-shows-promise-in-early-phase-trial/
Wildon Farwell, MD, Chief Medical Officer at Satellos, discusses the safety and efficacy of SAT-3247 to treat adults with Duchenne muscular dystrophy (DMD).
RARE DISEASE LEARNING CENTERS +++ +++
RARE DISEASE LEARNING CENTERS
Rett Syndrome
https://checkrare.com/rett-syndrome/
Rett syndrome is a multisystem disorder that primarily affects girls. Only in rare cases are boys affected (who may experience more severe symptoms). Multiple loss-of-function mutations to the MECP2 gene are the cause of Rett syndrome.
Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
https://checkrare.com/aromatic-l-amino-acid-decarboxylase-aadc-deficiency/
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare, genetic disorder that affects the central nervous systems of young patients. AADC deficiency is caused by defect in the dopa decarboxylase (DDC) gene, which leads to a reduction in the critical neurotransmitters dopamine, norepinephrine, epinephrine, and melatonin in the brain.
WHIM Syndrome
https://checkrare.com/whim-syndrome/
WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with severe neutropenia that affects all ages. The acronym “WHIM” stands for (W)arts, (H)ypogammaglobulinemia, (I)nfections, and (M)yelokathexis. Myelokathexis refers to an abnormal retention of white blood cells, in the bone marrow, that causes a reduction of immune fighting white blood cells, and most notably the reduction of neutrophils and lymphocytes.
CME PROGRAMS
Consider Rare: Suspecting and Diagnosing Hereditary Angioedema
https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/
Jonathan A Bernstein, MD, Professor of Medicine at the University of Cincinnati describes the early symptoms of HAE and its clinical relevance and best practices to diagnose HAE more efficiently to reduce diagnostic delays.
CREDITS: 0.5 CME | DURATION: 0.5 hours
EXPIRES: 5/15/2026 | FEE: $0
Fabry Disease Research Highlights
https://checkrare.com/learning/p-fabry-disease-research-highlights-2025/
Eric Wallace, MD, Professor of Medicine, Department of Nephrology at the University of Alabama Medical School, describes the latest research being presented to better manage individuals with Fabry disease and its clinical relevance.
CREDITS: 0.5 CME | DURATION: 0.5 hours
EXPIRES: 5/15/2026 | FEE: $0
Transforming Clinical Outcomes with Early Treatment of Lysosomal Disorders
https://checkrare.com/learning/p-transforming-clinical-outcomes-with-early-treatment-of-lysosomal-disorders/
Ozlem Goker-Alpan MD, David F. Kronn, MD, Uma Ramaswami FRCPCH, MD, Liz Jalazo, MD, and Lindsay Torrice MSN, CPNP-PC, examine the evidence available to address how to monitor, and possibly treat, children with lysosomal diseases that were diagnosed by newborn screening or soon after birth.
CREDITS: 1.00 CME | DURATION: 1 hour
EXPIRES: 4/3/2026 | FEE: $0
Is a 1% Benefit Really Practice-Changing? ++++ +++ ++ +++
Featured Commentaries
Is a 1% Benefit Really Practice-Changing?
https://www.medscape.com/viewarticle/esmo-2025-cutting-through-hype-real-data-and-real-math-2025a1000y0e?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
Black Coffee and Cancer Hype Unsubstantiated
https://www.medscape.com/viewarticle/black-coffee-and-cancer-hype-unsubstantiated-2025a1000y6o?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
The Next Frontier in Breast Reconstruction?
https://www.medscape.com/viewarticle/sensation-must-be-next-frontier-breast-reconstruction-2025a1000y6m?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
Does Treatment Timing Affect Chemoradiation Response?
https://www.medscape.com/viewarticle/circadian-rhythm-chemoradiation-does-treatment-timing-affect-2025a1000vzv?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
ESMO: Neoadjuvant Combo Confirms EFS Edge in Melanoma
https://www.medscape.com/viewarticle/esmo-neoadjuvant-combo-confirms-event-free-survival-edge-2025a1000yeu?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
AI Mining Patient Messages for Cancer Research
https://www.medscape.com/viewarticle/can-ai-use-patient-messages-identify-new-cancer-care-2025a1000wak?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
Cardiotoxicity Risk Lingers for Cancer Survivors
https://www.medscape.com/viewarticle/cardiotoxicity-risk-lingers-cancer-survivors-2025a1000uy4?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
Also of Interest
US Advanced Breast Cancer Survival Up, Global Progress Lags
https://www.medscape.com/viewarticle/us-advanced-breast-cancer-survival-global-progress-lags-2025a1000vup?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
US Advanced Breast Cancer Survival Up, Global Progress Lags
Will Pass
HER3-DXd Active Against Metastatic Breast Cancer, Brain Metastases
https://www.medscape.com/viewarticle/patritumab-deruxtecan-clinically-active-against-metastatic-2025a1000uo5?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
Patritumab Deruxtecan Clinically Active Against Metastatic Breast Cancer and Brain Metastases
Edited by Vineeta Teotia
US Drug Spotlight
Eculizumab
https://reference.medscape.com/drug/soliris-bkemv-eculizumab-342875?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
Cladribine
https://reference.medscape.com/drug/mavenclad-cladribine-342213?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
Vismodegib
https://reference.medscape.com/drug/erivedge-vismodegib-999716?ecd=mkm_ret_251228_mscpmrk_onc_perspectives_etid7988818&uac=148436CN&impID=7988818
Indicated for treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation
Contemporary Glioma Care: Innovation, Collaboration, and Transformation
Contemporary Glioma Care: Innovation, Collaboration, and Transformation
Diffuse gliomas of lower grade (LGGs) present complex challenges in neuro-oncology. Recent advances in molecular profiling have revolutionized our understanding of these tumors, primarily IDH-mutated astrocytomas and oligodendrogliomas, leading to more-precise classification and tailored treatments. Despite slower growth than high-grade disease, LGGs substantially affect younger adults, necessitating a delicate balance between aggressive treatment and neurological function preservation. This ACE collection explores cutting-edge research and innovative approaches to transforming LGG management, aiming to improve patient outcomes and quality of life. Stay current in this rapidly evolving field with our comprehensive learning resource hub.
https://www.medscape.org/advances/contemporary-glioma-care-2025a10005y2?src=ban_driv_042025_mscpedu_421033.01_ace
sábado, 27 de diciembre de 2025
RAS-Targeted Strategies in Pancreatic Cancer Progress and Future Directions CME/CNE/CPE Marriott Marquis San Francisco Friday, January 9, 2026 | 6:30 PM - 8:00 PM PT
https://na.eventscloud.com/website/91375/
This January in San Francisco, join a panel of 3 leading experts for a 90-minute program on the evolving landscape of pancreatic adenocarcinoma (PDAC) treatment. This dynamic discussion will focus on the remarkable evolution of renin-angiotensin system (RAS) inhibitors in PDAC, tracing the journey from when RAS was considered undruggable to the latest data on novel mechanisms and therapies targeting RAS in its active state. Don't miss this opportunity to gain insights into the future of PDAC management and engage with the experts directly during a dedicated question-and-answer session.
Not an official event of the 2026 ASCO® Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation
Nanozyme Hydrogel Directly Targets Cause of Diabetic Osteoarthritis
https://www.azonano.com/news.aspx?newsID=41596&utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=arthritis_newsletter_21_december_2025
Researchers have developed a nanozyme-integrated hydrogel that directly targets advanced glycation end products (AGEs), a key driver of diabetic osteoarthritis (DOA).
Arthritis and safeguarding joint health
https://www.news-medical.net/whitepaper/20251210/Arthritis-and-safeguarding-joint-health.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=arthritis_newsletter_21_december_2025
World Arthritis Day, observed each year on October 12, serves as a reminder of the widespread impact of this highly disabling disease. Rheumatoid Arthritis (RA), one of its most severe forms, impacts the health and quality of life of around 23.7 million individuals across the world.
Psoriasis and advancing skin health
https://www.news-medical.net/whitepaper/20251210/Psoriasis-and-advancing-skin-health.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=arthritis_newsletter_21_december_2025
October 29, World Psoriasis Day, was established to raise global awareness and promote an accurate understanding of psoriasis (PsO). The chronic, recurrent autoimmune disease is commonly associated with comorbidities that impact both the skin and systemic organs.
TikTok videos about gout often contain misleading informationTikTok videos about gout often contain misleading information +++
Wheelchair? Hearing aids? Yes. ‘Disabled?' No way.Wheelchair? Hearing aids? Yes. ‘Disabled?' No way.
https://www.news-medical.net/news/20251211/Wheelchair-Hearing-aids-Yes-e28098Disabled-No-way.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=arthritis_newsletter_21_december_2025
In her house in Ypsilanti, Michigan, Barbara Meade said, "there are walkers and wheelchairs and oxygen and cannulas all over the place."
EULAR proposes new guidance to assess disease activity in adult-onset Still’s diseaseEULAR proposes new guidance to assess disease activity in adult-onset Still’s disease
https://www.news-medical.net/news/20251212/EULAR-proposes-new-guidance-to-assess-disease-activity-in-adult-onset-Stille28099s-disease.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=arthritis_newsletter_21_december_2025
EULAR - The European Alliance of Associations for Rheumatology - has identified an unmet clinical need around the assessment of disease activity in people with adult-onset Still's disease.
TikTok videos about gout often contain misleading informationTikTok videos about gout often contain misleading information
https://www.news-medical.net/news/20251211/TikTok-videos-about-gout-often-contain-misleading-information.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=arthritis_newsletter_21_december_2025
A new paper in Rheumatology Advances in Practice, published by Oxford University Press, indicates that TikTok videos about gout are commonly misleading, inconsistent, or inaccurate.
Why female athletes need injury prevention rules built for women, not men
https://www.news-medical.net/news/20251208/Why-female-athletes-need-injury-prevention-rules-built-for-women-not-men.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=arthritis_newsletter_21_december_2025
A landmark IOC consensus sets out the first comprehensive, female-focused roadmap for preventing sports injuries, calling for changes in training, equipment, rules, and sporting culture to truly protect women and girls in sport.
Do leave-on benzoyl peroxide products present lower benzene risk than wash-off formulations? (Medscape AI)
https://www.medscape.com/ai-search?query=Do%20leave-on%20benzoyl%20peroxide%20products%20present%20lower%20benzene%20risk%20than%20wash-off%20formulations%3F&ecd=mkm_ret_251227_mscpmrk_derm_best-of-the-year_etid7981588&uac=148436CN&impID=7981588
Recent analyses suggest that leave-on benzoyl peroxide formulations tend to have lower benzene content compared with wash-off products. In particular, Valisure’s petition data and subsequent investigations by the FDA and academic groups have shown that leave-on products often contain benzene concentrations below those detected in some wash-off cleansers. One proposed explanation is that leave-on formulations are typically manufactured in smaller batches, allowing faster cooling post-production and thereby limiting the thermal generation of benzene during processing1.
Why Some Livers Can’t Recover After Alcohol Abstinence Eugenia Tsai, MD +++
https://www.medscape.com/viewarticle/why-some-livers-cant-recover-after-alcohol-abstinence-2025a1000wji?ecd=mkm_ret_251227_mscpmrk-OUS_InFocus_etid7965367&uac=148436CN&impID=7965367
Readiness-to-Change Scores Predict Alcohol Treatment Uptake
https://www.medscape.com/viewarticle/higher-readiness-change-scores-emergency-department-patients-2025a1000xa2?ecd=mkm_ret_251227_mscpmrk-OUS_InFocus_etid7965367&uac=148436CN&impID=7965367
Cannabis Users Should Be Wary of Weed’s Effects on the Heart
https://www.medscape.com/viewarticle/warn-your-patients-cannabis-use-can-have-serious-2025a1000waq?ecd=mkm_ret_251227_mscpmrk-OUS_InFocus_etid7965367&uac=148436CN&impID=7965367
The Brain’s ‘Gray Hairs’ a Common Referral Source ++++++ +++
Expert Insights
The Brain’s ‘Gray Hairs’ a Common Referral Source
https://www.medscape.com/viewarticle/brains-gray-hairs-common-referral-source-2025a1000s1h?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
Not What You Can Buy but What You Can Do: Wellness in PD
https://www.medscape.com/viewarticle/not-what-you-can-buy-what-you-can-do-holistic-approach-2025a1000x4v?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
How Does EBV Cause MS -- Hit and Run or Chronic Driver?
https://www.medscape.com/viewarticle/how-does-ebv-cause-multiple-sclerosis-hit-and-run-or-chronic-2025a1000uq8?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
McDonald Criteria Updates Boost MS Diagnostic Specificity
https://www.medscape.com/viewarticle/mcdonald-criteria-updates-boost-ms-diagnostic-specificity-2025a1000skj?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
The Glymphatic System: Not a Typo
https://www.medscape.com/viewarticle/glymphatic-system-not-typo-brains-lymphatic-system-2025a1000nh1?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
Do You Really See What I See?
https://www.medscape.com/viewarticle/do-you-really-see-what-i-see-2025a1000nq8?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
PRACTICE ESSENTIALS
Key Updates in Relapsing-Remitting Multiple Sclerosis
Key Updates in Relapsing-Remitting Multiple Sclerosis From ECTRIMS 2025
Patricia Coyle, MD
https://www.medscape.com/viewarticle/multiple-sclerosis-disease-modifying-therapy-rrms-ectrims-2025a1000112?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
October 17, 2025
Acute Migraine Treatment With Triptans
https://decisionpoint.medscape.com/neurology/viewarticle/920165?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
Anticipating Key Disease-Modifying Therapy Data for RRMS
ECTRIMS 2025: Anticipating Key Disease-Modifying Therapy Data for RRMS
Devon S. Conway, MD, MS
https://www.medscape.com/viewarticle/mdangle-ectrims-2025-dmt-in-rrms-preview-2025a1000hjq?ecd=mkm_ret_251227_mscpmrk_neuro_perspectives_etid7984775&uac=148436CN&impID=7984775
September 17, 2025
viernes, 26 de diciembre de 2025
New CMS models could reshape the landscape for lifestyle medicine practice and reimbursement ++++ ++++
New CMS models could reshape the landscape for lifestyle medicine practice and reimbursement
https://www.news-medical.net/news/20251212/New-CMS-models-could-reshape-the-landscape-for-lifestyle-medicine-practice-and-reimbursement.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
The American College of Lifestyle Medicine (ACLM) applauds two new Centers for Medicare and Medicaid Services (CMS) models that could significantly reshape the landscape for lifestyle medicine practice and reimbursement.
Plant-based diets support healthy growth when properly planned for children
https://www.news-medical.net/news/20251212/Plant-based-diets-support-healthy-growth-when-properly-planned-for-children.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
Plant-based diets support healthy growth when properly planned for childrenVegetarian and vegan diets can support healthy growth when carefully planned with appropriate supplementation, finds a major new meta-analysis – the most comprehensive study to-date of plant-based diets in children.
Lowering blood sugar reduces heart risk in prediabetes
https://www.news-medical.net/news/20251212/Lowering-blood-sugar-reduces-heart-risk-in-prediabetes.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
Lowering blood sugar levels halves the likelihood of serious heart problems in people with prediabetes.
Frequency and quantity of alcohol consumption influence cancer risk
https://www.news-medical.net/news/20251211/Frequency-and-quantity-of-alcohol-consumption-influence-cancer-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
As Americans gear up for the holiday season, new research offers a timely reminder to reflect on the long-term health effects of raising a celebratory glass – or two.
New research reveals underestimation of food insecurity
https://www.news-medical.net/news/20251213/New-research-reveals-underestimation-of-food-insecurity.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
New research reveals underestimation of food insecurityBefore you can address a problem, you need to understand its scope. That's why the United Nations developed the Integrated Food Security Phase Classification System. Aid organizations rely on analyses from this global partnership, which monitors and classifies the severity of food insecurity to help target assistance where and when it is most needed.
How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOS
https://www.news-medical.net/news/20251216/How-Traditional-Chinese-Medicine-may-reshape-the-gut-microbiome-to-ease-insulin-resistance-in-PCOS.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOSThis review synthesizes evidence that gut microbiota dysbiosis contributes to insulin resistance and symptom severity in polycystic ovary syndrome through impaired barrier function, inflammation, and altered microbial metabolites. It evaluates how Traditional Chinese Medicine may modulate these pathways while highlighting major gaps in clinical validation, safety, and standardization.
Many parents struggle to navigate conversations about nutrition with teens
https://www.news-medical.net/news/20251215/Many-parents-struggle-to-navigate-conversations-about-nutrition-with-teens.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
As teens gain more independence in their food choices, many parents struggle to navigate conversations about nutrition -which could be especially important during the holidays, when celebrations often center around meals.
Indiana University physician joins FDA panel on male hormone therapy
https://www.news-medical.net/news/20251212/Indiana-University-physician-joins-FDA-panel-on-male-hormone-therapy.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
Indiana University physician joins FDA panel on male hormone therapyHelen Bernie, DO, MPH, assistant professor of urology at Indiana University School of Medicine, will participate in an expert panel on testosterone replacement therapy and men's health to be held Wednesday, Dec. 10, by the U.S. Food and Drug Administration. Bernie's role on the panel is that of a clinical expert on men's reproductive health, which is the focus of both her practice and academic research.
High fructose intake increases fatty liver risk ++++ +++
High fructose intake increases fatty liver risk
https://www.news-medical.net/news/20251216/High-fructose-intake-increases-fatty-liver-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
High fructose intake increases fatty liver riskExcessive fructose intake from soft drinks is linked to liver damage and NAFLD. Lifestyle modifications are essential for effective prevention and treatment.
Unnecessary gluten-free diets may put children at risk
https://www.news-medical.net/news/20251215/Unnecessary-gluten-free-diets-may-put-children-at-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
Unnecessary gluten-free diets may put children at riskUnderstanding gluten-related disorders is crucial for pediatric nutrition, as gluten-free diets can pose health risks without appropriate medical supervision.
A new trial investigates whether the MIND diet can be scaled for obesity management
https://www.news-medical.net/news/20251214/A-new-trial-investigates-whether-the-MIND-diet-can-be-scaled-for-obesity-management.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
A new trial investigates whether the MIND diet can be scaled for obesity managementThis study protocol outlines a 12-week randomized trial testing whether a MIND diet intervention is feasible, acceptable, and sustainable for adults with obesity in Sweden. It will generate preliminary evidence on adherence, mental well-being, and gut microbiota changes to inform larger efficacy trials.
Scientists map how cinnamon’s bioactives interact with cancer signaling
https://www.news-medical.net/news/20251215/Scientists-map-how-cinnamone28099s-bioactives-interact-with-cancer-signaling.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
Scientists map how cinnamon’s bioactives interact with cancer signalingThis review synthesizes preclinical evidence showing that cinnamon-derived compounds can modulate inflammation, oxidative stress, apoptosis, and angiogenesis through multiple cancer-related signaling pathways. While biologically plausible, the findings are largely limited to cell and animal models, underscoring the need for pharmacokinetic, safety, and clinical validation.
Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic risk
https://www.news-medical.net/news/20251214/Swapping-high-carb-snacks-for-tree-nuts-cuts-food-cravings-in-young-adults-at-metabolic-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic riskDaily replacement of typical high-carbohydrate snacks with mixed tree nuts for 16 weeks reduced cravings for sweets and fast foods in young adults with early metabolic syndrome risk. This dietary swap improved overall diet quality, measured by the Healthy Eating Index, without increasing body weight or altering short-term glycaemic markers.
How ultra-processed foods shape Crohn’s disease risk and what dietary strategies can really help
https://www.news-medical.net/news/20251211/How-ultra-processed-foods-shape-Crohne28099s-disease-risk-and-what-dietary-strategies-can-really-help.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
How ultra-processed foods shape Crohn’s disease risk and what dietary strategies can really helpThis narrative review synthesizes evidence showing that higher intake of ultra-processed foods is consistently associated with increased Crohn’s disease risk, with mechanistic pathways implicating emulsifiers, carrageenan, maltodextrin, titanium dioxide, sweeteners and salt. It also highlights that minimally processed dietary strategies, including EEN and CDED, show therapeutic promise, particularly in pediatric Crohn’s disease.
What happens to your body during an ultramarathon? New study reveals key metabolic changes
https://www.news-medical.net/news/20251210/What-happens-to-your-body-during-an-ultramarathon-New-study-reveals-key-metabolic-changes.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
What happens to your body during an ultramarathon? New study reveals key metabolic changesThis study tracked ultramarathon runners across 100 km, 160.9 km, and 230 km events to examine real-world metabolic, hormonal, and muscle stress responses. Severe energy deficits, muscle damage, and heterogeneous hormonal shifts were observed, with the greatest strain seen in the 230 km distance.
What happens to your body when you eat takeaway food too often? +++++
https://www.news-medical.net/news/20251211/What-happens-to-your-body-when-you-eat-takeaway-food-too-often.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
New evidence reveals how frequent takeaway meals elevate dietary inflammation and quietly reshape key metabolic risk factors, underscoring why reducing high-frequency takeaway habits could meaningfully improve long-term heart and metabolic health.
What drinking kefir really does to your gut and oral microbiome
A comprehensive review of human studies reveals that kefir can alter certain gut and oral bacteria. However, inconsistent results and small trials mean its true health impact remains an open scientific question.
https://www.news-medical.net/news/20251215/What-drinking-kefir-really-does-to-your-gut-and-oral-microbiome.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
How much omega-3 do you need daily? New global review reveals DHA and EPA requirements
https://www.news-medical.net/news/20251210/How-much-omega-3-do-you-need-daily-New-global-review-reveals-DHA-and-EPA-requirements.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
Global and national guidelines for long-chain omega-3 intake vary widely across life stages, with many countries lacking clear recommendations. Most authorities advise at least 250 mg/day of EPA and DHA, yet population intakes remain far below optimal levels.
How specific foods reshape oxidative stress responses during and after high-intensity trainingHow specific foods reshape oxidative stress responses during and after high-intensity training
https://www.news-medical.net/news/20251211/How-specific-foods-reshape-oxidative-stress-responses-during-and-after-high-intensity-training.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
Carbohydrate-rich foods blunt acute oxidative stress during fasted high-intensity exercise, while polyphenol-rich foods accelerate early recovery by reducing post-exercise ROS. Findings highlight how nutrient timing shapes redox responses in sedentary young women undergoing resistance-circuit HIIT.
White bread vs wholegrain: which one is actually better for your health?White bread vs wholegrain: which one is actually better for your health?
https://www.news-medical.net/news/20251211/White-bread-vs-wholegrain-which-one-is-actually-better-for-your-health.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=nutrition_newsletter_18_december_2025
This review dispels common myths about white and wholegrain bread by examining their composition processing and health effects. It concludes that while wholegrain breads offer added benefits white bread remains a safe affordable and nutritionally meaningful staple when fortified.
Comparison of vasopressin-first weaning versus norepinephrine-first weaning in critically ill patients. Maram Alshreef, Hanin AbaAlkhayl, Qoot Almdainy, Abdulaziz Alshammari, Shahad Alajmi, Shatha Alruwaite, Ebtisam Alqahtani, Reema Almalke, Tagreed Alonazi International Journal of Clinical Pharmacology and Therapeutics 2025 December 5
https://read.qxmd.com/read/41347381/comparison-of-vasopressin-first-weaning-versus-norepinephrine-first-weaning-in-critically-ill-patients?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug
Comparison of vasopressin-first weaning versus norepinephrine-first weaning in critically ill patients.
Septic shock is a critical condition requiring vasopressor support and mechanical ventilation. The sequence of vasopressor weaning may affect clinical outcomes,..
Dec 5, 2025: International Journal of Clinical Pharmacology and Therapeutics
Rab23 GTPase and IFT43 regulate the trafficking of prostaglandin E receptor 4 to primary cilia. Yewei Chen, Yating Zhou, Yao Qi, Tingting Miao, Jianan Shi, Daqing Jin, Tao P Zhong Communications Biology 2025 December 10
https://read.qxmd.com/read/41372612/rab23-gtpase-and-ift43-regulate-the-trafficking-of-prostaglandin-e-receptor-4-to-primary-cilia?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug
Rab23 GTPase and IFT43 regulate the trafficking of prostaglandin E receptor 4 to primary cilia.
Primary cilia are crucial organelles involved in various cellular signaling pathways. Prostaglandin E receptor 4 (EP4), a G protein-coupled receptor (GPCR), loc..
Dec 10, 2025: Communications Biology
What is the impact of nutrition interventions on incidence of anastomotic leak after colorectal surgery? A systematic review of randomized trials. Leslee Hasil, Andrew Milks, Angelea Panagakos, Dominique Engel, Emily Jaeger-McEnroe, Chelsia Gillis European Journal of Surgical Oncology 2025 December 4
https://read.qxmd.com/read/41401601/what-is-the-impact-of-nutrition-interventions-on-incidence-of-anastomotic-leak-after-colorectal-surgery-a-systematic-review-of-randomized-trials?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug
What is the impact of nutrition interventions on incidence of anastomotic leak after colorectal surgery? A systematic review of randomized trials.
Nutrition-related factors have been associated with increased incidence of anastomotic leak (AL) following colorectal surgery; however, specific perioperative n..
Dec 4, 2025: European Journal of Surgical Oncology
Suscribirse a:
Comentarios (Atom)
.png)
